EVOKE PHARMA INC (EVOK) Fundamental Analysis & Valuation

NASDAQ:EVOK • US30049G3020

Current stock price

11 USD
+0.04 (+0.36%)
Last:

This EVOK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. EVOK Profitability Analysis

1.1 Basic Checks

  • EVOK had negative earnings in the past year.
  • EVOK had a negative operating cash flow in the past year.
  • In the past 5 years EVOK always reported negative net income.
  • In the past 5 years EVOK always reported negative operating cash flow.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • EVOK's Return On Assets of -33.40% is in line compared to the rest of the industry. EVOK outperforms 48.96% of its industry peers.
  • EVOK has a Return On Equity of -155.44%. This is in the lower half of the industry: EVOK underperforms 70.83% of its industry peers.
Industry RankSector Rank
ROA -33.4%
ROE -155.44%
ROIC N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • EVOK has a Gross Margin of 97.02%. This is amongst the best in the industry. EVOK outperforms 96.35% of its industry peers.
  • In the last couple of years the Gross Margin of EVOK has grown nicely.
  • The Profit Margin and Operating Margin are not available for EVOK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EVOK Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for EVOK has been increased compared to 1 year ago.
  • The number of shares outstanding for EVOK has been reduced compared to 5 years ago.
  • EVOK has a better debt/assets ratio than last year.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • EVOK has an Altman-Z score of -10.88. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -10.88, EVOK is not doing good in the industry: 73.96% of the companies in the same industry are doing better.
  • EVOK has a Debt/Equity ratio of 1.49. This is a high value indicating a heavy dependency on external financing.
  • EVOK has a worse Debt to Equity ratio (1.49) than 77.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Altman-Z -10.88
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

  • EVOK has a Current Ratio of 1.27. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
  • EVOK has a Current ratio of 1.27. This is in the lower half of the industry: EVOK underperforms 78.13% of its industry peers.
  • EVOK has a Quick Ratio of 1.22. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
  • EVOK has a worse Quick ratio (1.22) than 73.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.22
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. EVOK Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.89% over the past year.
  • Looking at the last year, EVOK shows a very strong growth in Revenue. The Revenue has grown by 67.40%.
  • Measured over the past years, EVOK shows a very strong growth in Revenue. The Revenue has been growing by 84.95% on average per year.
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.13%
Revenue 1Y (TTM)67.4%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%61.42%

3.2 Future

  • EVOK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.00% yearly.
  • Based on estimates for the next years, EVOK will show a very strong growth in Revenue. The Revenue will grow by 52.59% on average per year.
EPS Next Y57.76%
EPS Next 2Y46.72%
EPS Next 3Y35%
EPS Next 5YN/A
Revenue Next Year59.35%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

4

4. EVOK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EVOK. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 15.86, which indicates a correct valuation of EVOK.
  • Based on the Price/Forward Earnings ratio, EVOK is valued cheaper than 80.21% of the companies in the same industry.
  • EVOK's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.24.
Industry RankSector Rank
PE N/A
Fwd PE 15.86
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • EVOK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as EVOK's earnings are expected to grow with 35.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EVOK Dividend Analysis

5.1 Amount

  • No dividends for EVOK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVOK Fundamentals: All Metrics, Ratios and Statistics

EVOKE PHARMA INC

NASDAQ:EVOK (12/16/2025, 8:19:05 PM)

11

+0.04 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-11
Inst Owners34.75%
Inst Owner Change0%
Ins Owners10.48%
Ins Owner Change-1.39%
Market Cap18.92M
Revenue(TTM)14.42M
Net Income(TTM)-5.23M
Analysts43.33
Price Target18.36 (66.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.33%
Min EPS beat(2)-102.61%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-37.55%
Min EPS beat(4)-102.61%
Max EPS beat(4)1.96%
EPS beat(8)3
Avg EPS beat(8)-39.3%
EPS beat(12)6
Avg EPS beat(12)-23.46%
EPS beat(16)8
Avg EPS beat(16)-20.74%
Revenue beat(2)0
Avg Revenue beat(2)-3.01%
Min Revenue beat(2)-3.1%
Max Revenue beat(2)-2.92%
Revenue beat(4)1
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-8.93%
Max Revenue beat(4)5.18%
Revenue beat(8)2
Avg Revenue beat(8)-8.52%
Revenue beat(12)4
Avg Revenue beat(12)-6.52%
Revenue beat(16)5
Avg Revenue beat(16)-6.98%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.08%
EPS NY rev (1m)4.08%
EPS NY rev (3m)4.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.29%
Revenue NY rev (1m)1%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.86
P/S 1.31
P/FCF N/A
P/OCF N/A
P/B 5.63
P/tB 5.63
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)0.69
Fwd EY6.31%
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS8.39
BVpS1.95
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -33.4%
ROE -155.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.02%
FCFM N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score5
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.22
Altman-Z -10.88
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.13%
EPS Next Y57.76%
EPS Next 2Y46.72%
EPS Next 3Y35%
EPS Next 5YN/A
Revenue 1Y (TTM)67.4%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%61.42%
Revenue Next Year59.35%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y11.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.97%
OCF growth 3YN/A
OCF growth 5YN/A

EVOKE PHARMA INC / EVOK Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EVOKE PHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to EVOK.


Can you provide the valuation status for EVOKE PHARMA INC?

ChartMill assigns a valuation rating of 4 / 10 to EVOKE PHARMA INC (EVOK). This can be considered as Fairly Valued.


What is the profitability of EVOK stock?

EVOKE PHARMA INC (EVOK) has a profitability rating of 2 / 10.


What is the financial health of EVOKE PHARMA INC (EVOK) stock?

The financial health rating of EVOKE PHARMA INC (EVOK) is 2 / 10.


Can you provide the expected EPS growth for EVOK stock?

The Earnings per Share (EPS) of EVOKE PHARMA INC (EVOK) is expected to grow by 57.76% in the next year.